Liraglutide can promote the secretion, proliferation and regeneration of islet cells, inhibit appetite, reduce weight, blood pressure and lipid

Liraglutide can promote the secretion, proliferation and regeneration of islet cells, inhibit appetite, reduce weight, blood pressure and lipid

When we eat carbohydrates or sugars, it will stimulate the intestinal secretion of two kinds of incretin, incretin, as the name suggests, is to promote the synthesis and release of insulin, hypoglycemic substances. One of them is glucagon like peptide 1, sitagliptin, agliptin, vildagliptin and other statins, mainly by inhibiting the hydrolysis of glucagon like peptide 1 enzyme, so as to improve its concentration.

And another kind of hypoglycemic drugs, liraglutide, benaluptide, exenatide, dulaglycopeptide, lisnatide, etc., must be familiar to everyone, especially liraglutide. This new class of hypoglycemic drugs is called glucagon like peptide-1 receptor agonists. As the name suggests, it is to activate the receptor of glucagon like peptide 1 and play the same hypoglycemic effect as glucagon like peptide 1. It looks a little bit like a statin.

These drugs can increase the secretion of insulin, enhance the sensitivity of peripheral tissues to insulin, and reduce postprandial blood glucose in a glucose concentration dependent manner by simulating the action of human glucagon like peptide-1 receptor. At the same time, it can inhibit the secretion of glucagon, delay gastric emptying, and reduce food intake by inhibiting the central appetite, so as to play the role of reducing blood glucose.

Liraglutide also has the effect of weight loss

Liraglutide also has the effect of weight loss, and the risk of hypoglycemia is not obvious when used alone. In addition, liraglutide also has the effect of reducing blood pressure and blood lipid. It can reduce the total cholesterol, triglyceride and low density lipoprotein cholesterol in patients with type 2 diabetes.

Animal and in vitro studies have shown that liraglutide not only can promote insulin secretion in a Glucose dependent manner, but also can promote the proliferation and regeneration of islet β cells, reduce the apoptosis of β cells, increase the expression of insulin secretion genes, and solve the problem from the root.

At present, based on the results of cardiovascular clinical studies, liraglutide and dulaglutide show better cardiovascular protection, while the cardiovascular protection of lisnatide and exenatide is neutral, and there is still a lack of research data on benaluptide and losartan.

Therefore, for patients with atherosclerotic cardiovascular disease or type 2 diabetes mellitus with high risk factors of cardiovascular disease, it is recommended to combine liraglutide and dulaglycopeptide with evidence of cardiovascular benefits to reduce cardiovascular events, regardless of whether glycosylated hemoglobin is up to standard.

A large number of clinical trials have shown that liraglutide can significantly reduce urinary protein excretion

A large number of clinical trials have shown that liraglutide can significantly reduce urinary protein excretion, thereby reducing the risk of adverse renal outcomes in patients with type 2 diabetes mellitus by about 17%. From the perspective of cardiovascular protection and improving blood glucose control, patients with type 2 diabetes mellitus complicated with chronic kidney disease can consider choosing such hypoglycemic drugs.

Liraglutide can be used alone, or as a dual or triple drug with other hypoglycemic drugs besides sitagliptin (sitagliptin, saxagliptin, etc.). Especially, the combination with metformin is better in reducing fasting blood glucose, glycosylated hemoglobin, weight loss, blood glucose compliance rate and so on.

Most of these drugs can be used in patients with mild to moderate renal insufficiency, liraglutide and dulaglutide can be used in patients with severe renal insufficiency whose creatinine clearance rate is more than 15. Liraglutide can be used in patients with mild to moderate liver dysfunction, and lisnatide and dulaglutide can be used in patients with liver dysfunction.

These drugs can be used in type 2 diabetic patients with heart failure risk, but they can not prevent heart failure. Diabetic patients with heart failure are advised to use dagliejing, engliejing and cagliejing. These drugs should be used with caution in the decompensated period of decreased ejection fraction. It is also not recommended for patients with pancreatitis.

When liraglutide is added to the double or triple hypoglycemic treatment regimen containing glixx or insulin, it is suggested to reduce the dosage of glixx or insulin or stop one of them to reduce the risk of hypoglycemia.

In short, liraglutide, as one of the three hypoglycemic drugs with cardiovascular and renal protective effects, plays an important role in patients with diabetes mellitus complicated with atherosclerosis and chronic kidney disease, which is worthy of more sugar friends’ understanding.